Biolinerx Stock Price, News & Analysis

BioLineRx Ltd. (NASDAQ: BLRX) will announce its unaudited financial results for Q1 2021 on May 26, 2021, before US market opening. A conference call featuring CEO Philip Serlin will take place at 10:00 a.m. EDT on the same day, accessible via the company’s Investor Relations page. The call can be dialed in through +1-866-744-5399 (US) or +972-3-918-0610 (internationally). A replay will be available for two hours post-call and until May 28 at +1-888-295-2634 (US) and +972-3-925-5904 (internationally).

BioLineRx Ltd. (NASDAQ: BLRX) reported favorable top-line results from its GENESIS Phase 3 trial of Motixafortide for bone marrow transplantation in multiple myeloma patients. The trial showed a 4.9-fold increase in patients mobilizing ≥ 6 million CD34+ cells/kg with Motixafortide plus G-CSF, indicating significant efficacy. Additionally, 88.3% of patients achieved transplantation after just one apheresis session. The safety profile was also noted as acceptable. BioLineRx aims to submit an NDA for regulatory approval in the first half of 2022.

BioLineRx Ltd. (NASDAQ: BLRX) announced the presentation of a poster at the AACR Annual Meeting, detailing a Phase 2a study of motixafortide in combination with KEYTRUDA and chemotherapy for metastatic pancreatic cancer. The study, which evaluated 38 patients, highlighted the challenges faced by patients with liver metastases. Key findings include a median overall survival (mOS) of 6.5 months and an overall response rate (ORR) of 21.1%. The company aims to advance discussions for potential collaborations and anticipates final data from a Phase 3 study in stem cell mobilization soon.

BioLineRx Ltd. (NASDAQ: BLRX) reported its financial results for 2020, highlighting positive interim data from its GENESIS Phase 3 trial of motixafortide for stem-cell mobilization, leading to early enrollment cessation. The firm anticipates NDA submission in the first half of 2022. Additionally, the triple combination study of motixafortide with KEYTRUDA and chemotherapy demonstrated improved outcomes in stage IV pancreatic cancer. The year ended with a net loss of $30 million, but the company bolstered its finances with $34.5 million from a public offering, supporting continued development of motixafortide and AGI-134.

BioLineRx Ltd. (NASDAQ: BLRX) will announce its 2020 financial results on February 23, 2021, before US markets open. A conference call is scheduled for the same day at 10:00 a.m. EST, featuring CEO Philip Serlin. Investors can join via the Investor Relations page. The company's lead program, Motixafortide, focuses on oncology and has undergone successful trials. BioLineRx is also advancing a second program, AGI-134, an immunotherapy for solid tumors.

BioLineRx Ltd. (NASDAQ: BLRX) announced the closing of its underwritten offering of 14,375,000 American Depositary Shares (ADSs) at $2.40 each, raising approximately $34.5 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., included the full exercise of their option for an additional 1,875,000 ADSs. Proceeds will support general corporate purposes, including working capital and clinical trials. BioLineRx, focused on oncology, is advancing its lead program Motixafortide and developing AGI-134 for cancer treatment.

BioLineRx Ltd. (NASDAQ: BLRX) announced an increase in its offering of American Depositary Shares (ADSs) to 12.5 million at $2.40 each due to demand, expecting gross proceeds of around $30 million. The offering is set to close on or about January 22, 2021. The underwriter, H.C. Wainwright & Co., has a 30-day option to purchase an additional 1.875 million ADSs. The proceeds will be used for corporate purposes, including funding clinical trials. The offering follows a previously filed shelf registration with the SEC.

BioLineRx Ltd. (NASDAQ: BLRX) announced an underwriting agreement with H.C. Wainwright & Co. for the purchase of 4,166,667 American Depositary Shares (ADSs) at $2.40 each. The offering is expected to close around January 22, 2021, with gross proceeds estimated at $10 million. The funds will be utilized for general corporate purposes, including funding clinical trials. The underwriter also holds a 30-day option to purchase an additional 625,000 ADSs. This offering follows a recently effective shelf registration statement filed with the SEC.

BioLineRx reported results from the COMBAT/KEYNOTE-202 study on motixafortide (BL-8040) for stage IV pancreatic cancer, showing significant efficacy improvements over historical data. The study involved 43 patients, yielding a median overall survival of 6.5 months (vs. 4.7 months historical) and a confirmed overall response rate of 13.2% (vs. 7.7% historical). The combination was well-tolerated with safety advantages noted, including lower instances of grade 3 neutropenia and infections. The results underscore the potential of motixafortide in improving treatment outcomes for pancreatic ductal adenocarcinoma patients.